Diagnostic Strategies for Urologic Cancer Using Expression Analysis of Various Oncogenic Surveillance Molecules—From Non-Coding Small RNAs to Cancer-Specific Proteins
Source abstract
Abstract
Urinary-tract-related tumors are prone to simultaneous or heterogeneous multiple tumor development within the primary organ. Urologic tumors have a very high risk of recurrence in the long and short term. This may be related to the disruption of homeostasis on the genetic level, such as the induction of genetic mutations due to exposure to various carcinogenic factors and the disruption of cancer suppressor gene functions. It is essential to detect the cancer progression signals caused by genetic abnormalities and find treatment therapies. In this review, we discuss the usefulness of tumor-expressing clinical biomarkers for predicting cancer progression. Furthermore, we discuss various factors associated with disturbed intracellular signals and those targeted by microRNAs, which are representative of non-coding small RNAs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer-related molecular mechanisms research · MicroRNA in disease regulation · RNA modifications and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Diagnostic Pathology, School of Medicine, Nara Medical University, Kashihara 634-8522, Nara, Japan
Department of Diagnostic Pathology, Nara City Hospital, Nara 630-8305, Nara, Japan
Funding
Japanese Ministry of Education, Culture, Sports, Science, and Technology
References (100+)
Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21492 ↗
2. EGFR Mutations and Lung Cancer10.1146/annurev-pathol-011110-130206 ↗
3. The role of the ALK receptor in cancer biology10.1093/annonc/mdw301 ↗
4. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma10.1056/NEJMoa1817323 ↗
5. RET revisited: Expanding the oncogenic portfolio10.1038/nrc3680 ↗
6. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death10.1016/j.eururo.2016.11.033 ↗
7. BRAF V600E mutation-specific antibody: A review10.1053/j.semdp.2015.02.010 ↗
8. c-Met expression in renal cell carcinoma with bone metastases10.1016/j.jbo.2020.100315 ↗
9. Molecular epidemiology and diagnostics of KRAS mutations in human cancer10.1007/s10555-020-09915-5 ↗
10. Vietri, M., D’Elia, G., Caliendo, G., Resse, M., Casamassimi, A., Passariello, L., Albanese, L., Cioffi, M., and Molinari, A. (2021). Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. Int. J. Mol. Sci., 22.10.3390/ijms22073753 ↗
11. The Potential of MicroRNAs as Prostate Cancer Biomarkers10.1016/j.eururo.2015.12.054 ↗
12. MicroRNA Signature in Renal Cell Carcinoma10.3389/fonc.2020.596359 ↗
13. MicroRNAs in cancer: Biomarkers, functions and therapy10.1016/j.molmed.2014.06.005 ↗
14. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder
15. MicroRNA-associated carcinogenesis in lung carcinoma10.4103/0973-1482.187283 ↗
16. Circular RNAs in renal cell carcinoma: Implications for tumorigenesis, diagnosis, and therapy10.1186/s12943-020-01266-7 ↗
17. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function10.1016/S0092-8674(04)00045-5 ↗
18. MicroRNA Signatures in Human Cancers10.1038/nrc1997 ↗
19. MicroRNA expression and function in cancer10.1016/j.molmed.2006.10.006 ↗
20. Prediction of Mammalian MicroRNA Targets10.1016/S0092-8674(03)01018-3 ↗
21. International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality10.1016/j.eururo.2014.10.002 ↗
22. miRNA-regulated cancer stem cells: Understanding the property and the role of miRNA in carcinogenesis10.1007/s13277-016-5156-1 ↗
23. Micro-RNAs: The New Potential Biomarkers in Cancer Diagnosis, Prognosis and Cancer Therapy
24. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer10.1016/j.bbrc.2014.11.056 ↗
25. Fujii, T., Shimada, K., Tatsumi, Y., Hatakeyama, K., Obayashi, C., Fujimoto, K., and Konishi, N. (2015). microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer, 15.10.1186/s12885-015-1846-0 ↗
26. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors10.5507/bp.2015.050 ↗
27. Epidemiology of Renal Cell Carcinoma10.14740/wjon1279 ↗
28. Obesity That Makes Kidney Cancer More Likely but Helps Fight It More Strongly10.1093/jnci/djt348 ↗
29. Ochratoxin A: Developmental and Reproductive Toxicity—An Overview10.1002/bdrb.21091 ↗
30. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies10.1016/S0140-6736(08)60269-X ↗
31. Epidemiology and screening for renal cancer10.1007/s00345-018-2286-7 ↗
32. Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence10.1007/BF02549723 ↗
33. Renal Cell Carcinoma: Long-Term Survival and Late Recurrence10.1016/S0022-5347(17)54359-1 ↗
34. Renal cryoablation: Five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma10.1080/21681805.2020.1794954 ↗
35. MicroRNAs in the Pathogenesis of Renal Cell Carcinoma and Their Diagnostic and Prognostic Utility as Cancer Biomarkers10.5301/jbm.5000174 ↗
36. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma10.1007/s12253-017-0323-2 ↗
37. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer10.1093/carcin/bgr302 ↗
38. Lei, Z., Klasson, T.D., Brandt, M.M., Van De Hoek, G., Logister, I., Cheng, C., Doevendans, P.A., Sluijter, J.P.G., and Giles, R.H. (2020). Control of Angiogenesis via a VHL/miR-212/132 Axis. Cells, 9.10.3390/cells9041017 ↗
39. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau–inactivated clear cell renal cell carcinoma
40. VHL-Regulated MiR-204 Suppresses Tumor Growth through Inhibition of LC3B-Mediated Autophagy in Renal Clear Cell Carcinoma10.1016/j.ccr.2012.02.019 ↗
41. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers10.1002/cam4.2583 ↗
42. Qin, Z., Hu, H., Sun, W., Chen, L., Jin, S., Xu, Q., Liu, Y., Yu, L., and Zeng, S. (2021). miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. Cancers, 13.10.3390/cancers13040618 ↗
43. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma10.1080/1061186X.2018.1479755 ↗
44. microRNA-107 functions as a candidate tumor suppressor gene in renal clear cell carcinoma involving multiple genes
45. Investigation of VHL gene associated with miR-223 in clear cell renal cell carcinoma10.1007/s11033-021-07025-1 ↗
46. Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma10.7150/jca.2.515 ↗
47. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk10.1002/mc.21917 ↗
48. MicroRNA-497 targets hepatoma-derived growth factor and suppresses human prostate cancer cell motility10.3892/mmr.2016.4756 ↗
49. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals10.1038/s41598-019-39646-9 ↗
50. Targeting the HIF2–VEGF axis in renal cell carcinoma10.1038/s41591-020-1093-z ↗
51. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook10.1016/j.ctrv.2020.102017 ↗
52. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma10.1007/s11255-018-1841-x ↗
53. Oto, J., Herranz, R., Plana, E., Sánchez-González, J., Pérez-Ardavín, J., Hervás, D., Fernández-Pardo, Á., Cana, F., Vera-Donoso, C., and Martínez-Sarmiento, M. (2021). Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and a Profile of Dysregulated microRNAs. Int. J. Mol. Sci., 22.10.3390/ijms22157913 ↗
54. MicroRNA-30a-5pme: A novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples10.1186/s13046-020-01600-3 ↗
55. Urinary microRNA in kidney disease: Utility and roles10.1152/ajprenal.00368.2018 ↗
56. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—2019 Update10.1016/j.eururo.2019.08.016 ↗
57. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes10.1016/j.eururo.2015.08.037 ↗
58. Fujii, T., Shimada, K., Nakai, T., and Ohbayashi, C. (2018). MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy. J. Clin. Med., 7.10.3390/jcm7050098 ↗
59. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines10.1016/j.eururo.2020.03.055 ↗
60. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder
61. Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis10.1038/s41598-019-41844-4 ↗
62. Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder10.1136/bcr-2018-228017 ↗
63. Hualin, S., Yu, J., Song, H., Zhu, S., Sun, L., Shang, Z., and Niu, Y. (2017). Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. BMC Cancer, 17.10.1186/s12885-017-3520-1 ↗
64. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder10.1177/1073274818800269 ↗
65. Inclusion of a Molecular Marker of Bladder Cancer in a Clinical Pathway for Investigation of Haematuria May Reduce the Need for Cystoscopy
66. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure
67. The Promise of Novel Molecular Markers in Bladder Cancer10.3390/ijms151223897 ↗
68. Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?
69. Urinary BTA: Indicator of bladder cancer or of hematuria10.1007/s00345-012-0935-9 ↗
70. The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer10.1016/j.juro.2017.08.097 ↗
71. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study10.7150/ijms.19929 ↗
72. Urinary exosomal shuttle RNA: Promising cancer diagnosis biomarkers of lower urinary tract10.1177/1724600819827023 ↗
73. Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer10.1007/s11033-021-06451-5 ↗
74. Diagnostic Value of Combination of MicroRNA-192 in Urinary Sediment and B-Ultrasound for Bladder Cancer10.1177/1533033819894573 ↗
75. Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria10.1002/ijc.31849 ↗
76. Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer10.1002/jso.23937 ↗
77. Zhang, D.-Z., Lau, K.-M., Chan, E.S.Y., Wang, G., Szeto, C.-C., Wong, K., Choy, R.K.W., and Ng, C.-F. (2014). Cell-Free Urinary MicroRNA-99a and MicroRNA-125b Are Diagnostic Markers for the Non-Invasive Screening of Bladder Cancer. PLoS ONE, 9.10.1371/journal.pone.0100793 ↗
78. Circulating miRNA panels for specific and early detection in bladder cancer10.1111/cas.13856 ↗
79. Urinary miRNA profiles discriminate between obstruction-induced bladder dysfunction and healthy controls10.1038/s41598-021-89535-3 ↗
80. Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer10.1007/s12032-014-0197-z ↗
81. Aberrant expression of microRNAs in bladder cancer10.1038/nrurol.2013.113 ↗
82. Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study10.1007/s00270-016-1322-5 ↗
83. Prostate Cancer Screening—A Perspective on the Current State of the Evidence10.1056/NEJMsb1616281 ↗
84. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells10.1002/path.4271 ↗
85. MicroRNA-466 inhibits cancer cell migration and invasion in hepatocellular carcinoma by indirectly mediating the downregulation of ROCK2
86. The Circular RNA circXPO1 Promotes Tumor Growth via Sponging MicroRNA-23a in Prostate Carcinoma
87. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer10.1016/j.celrep.2020.108585 ↗
88. MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma10.2147/OTT.S92314 ↗
89. Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer10.1002/mc.22381 ↗
90. LncRNA TUC338 is overexpressed in prostate carcinoma and downregulates miR-46610.1016/j.gene.2019.05.026 ↗
91. LncRNA FGF14-AS2 represses growth of prostate carcinoma cells via modulating miR-96-5p/AJAP1 axis10.1002/jcla.24012 ↗
92. MicroRNA-185 downregulates androgen receptor expression in the LNCaP prostate carcinoma cell line10.3892/mmr.2015.3332 ↗
93. MicroRNA-122 downregulates Rho-associated protein kinase 2 expression and inhibits the proliferation of prostate carcinoma cells
94. Hsa-miR-149-5p Suppresses Prostate Carcinoma Malignancy by Suppressing RGS1710.2147/CMAR.S281968 ↗
95. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis10.1172/JCI73531 ↗
96. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue10.1515/cclm-2014-1000 ↗
97. The utility of urine-circulating miRNAs for detection of prostate cancer10.1038/bjc.2016.233 ↗
98. Relevance function of microRNA-708 in the pathogenesis of cancer10.1016/j.cellsig.2019.109390 ↗
99. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma10.1016/j.biopha.2019.109109 ↗
100. MicroRNA-145 inhibits proliferation and induces apoptosis in human prostate carcinoma by upregulating long non-coding RNA GAS5